Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Leukemia Research|June 24, 2016
Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature reviewEric Grignano, Arsene Mekinian, Thorsten Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 studyCecile Pautas, Fatiha Merabet, Xavier Thomas, et al.
Haematologica|July 21, 2018
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL groupLionel Adès, Xavier Thomas, Agnes Guerci Bresler, et al.
Leukemia Research|November 22, 2019
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemiasAline Massé, Louise Roulin, Justine Pasanisi, et al.
Blood|June 22, 2011
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 studyXavier Thomas, Mohamed Elhamri, Emmanuel Raffoux, et al.
Biomedicines|November 27, 2021
Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)Hanane Djamai, Jeannig Berrou, Mélanie Dupont, et al.
Oncotarget|February 5, 2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndromeEmmanuel Raffoux, Audrey Cras, Christian Recher, et al.
Haematologica|July 9, 2013
The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrestRaouf Ben Abdelali, Vahid Asnafi, Arnaud Petit, et al.
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Leukemia Research|June 1, 2012
Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trialXavier Thomas, Emmanuel Raffoux, Aline Renneville, et al.
Pageof 8